KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Capital Expenditures (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Capital Expenditures data on record, last reported at -$29.7 million in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 216.38% year-over-year to -$29.7 million; the TTM value through Dec 2025 reached $478000.0, down 98.94%, while the annual FY2025 figure was $478000.0, 98.94% down from the prior year.
  • Capital Expenditures reached -$29.7 million in Q4 2025 per IONS's latest filing, down from $5.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $25.5 million in Q4 2024 and bottomed at -$29.7 million in Q4 2025.
  • Average Capital Expenditures over 5 years is $4.9 million, with a median of $4.4 million recorded in 2021.
  • Peak YoY movement for Capital Expenditures: soared 3213.19% in 2024, then tumbled 216.38% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $2.5 million in 2021, then skyrocketed by 65.43% to $4.1 million in 2022, then crashed by 119.79% to -$819000.0 in 2023, then skyrocketed by 3213.19% to $25.5 million in 2024, then crashed by 216.38% to -$29.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$29.7 million in Q4 2025, $5.3 million in Q3 2025, and $12.3 million in Q2 2025.